Etanercept

Therapeutic Etanercept antibody from the original Enbrel® and biosimilar commercial drugs.

Reference Standard as Aliquots

Enbrel®
Filters Sort results
Reset Apply
Product Batch
Therapeutic Expiry Date
Brand & Origin
Amount per Aliquot
Select Quantity
Discount
Price per Aliquot
Etanercept FL6599
2024.01
Enbrel®
DE
6 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
259,00 € /aliquot
Add to Wishlist
Etanercept LK4828
2024.01
Enbrel®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
234,00 € /aliquot
Add to Wishlist
Etanercept S67398
2019.02
Enbrel®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
234,00 € /aliquot
Add to Wishlist
Etanercept T21782
2019.04
Enbrel®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
197,00 € /aliquot
Add to Wishlist
Etanercept T64915
2019.06
Enbrel®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
197,00 € /aliquot
Add to Wishlist
Etanercept W02981
2019.08
Enbrel®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
197,00 € /aliquot
Add to Wishlist
Etanercept W32559
2019.12
Enbrel®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
234,00 € /aliquot
Add to Wishlist
Etanercept W42283
2019.10
Enbrel®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
197,00 € /aliquot
Add to Wishlist
Etanercept X44248
2020.04
Enbrel®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
197,00 € /aliquot
Add to Wishlist

Biosimilars as Aliquots​

Erelzi®, Benepali®, Nepexto®
Filters Sort results
Reset Apply
Product Batch
Therapeutic Expiry Date
Brand & Origin
Amount per Aliquot
Select Quantity
Discount
Price per Aliquot
Etanercept 211019088
2023.04
Erelzi®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
272,00 € /aliquot
Add to Wishlist
Etanercept GR206474
2023.11
Benepali®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
272,00 € /aliquot
Add to Wishlist
Etanercept Y10005702
2023.08
Nepexto®
DE
4 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
272,00 € /aliquot
Add to Wishlist

Access Batch Specific Analytical Information

Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API). ​

Request an Offer​

and Download a Sample Report​

1. Choose your method(s) of interest
2. Provide your contact details
3. Send us your request and receive a downloadable sample report


Please provide your contact information


send us your inquiry and download a free sample file


Product Information

Here you will find the product information for the reference product.

Enbrel® / Etanercept Reference Product

Drug nameEnbrel®
INNEtanercept
API typeEtanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. This Fc component contains the hinge, CH2and CH3regions, but not the CH1region of IgG1. Etanercept contains 934amino acids and has an apparent molecular weight of approximately 150 kilodaltons. The specific activity of etanercept is 1.7x 106units/mg.
Pharmacotherapeutic group
Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors
ATC code
L04AB01
Target of antibody
TNF-α; Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
General function
Short descriptionTumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55- kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.
TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. Etanercept may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/99/126/001 - 022
Marketing authorisation holder
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma KG
Birkendorfer Strasse 65
D-88397 Biberach an der Riss
Germany

Pfizer Ireland Pharmaceuticals
Grange Castle Business Park
Clondalkin
Dublin 22
Ireland
Name and address of the manufacturer(s) responsible for batch releaseWyeth Pharmaceuticals
New Lane
Havant
Hampshire, PO9 2NG
United Kingdom
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Powder: Mannitol (E421) Sucrose
Trometamol
Solvent: Water for injections

Support

Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!

Ready to simplify your sourcing?

Here’s how to get started:

Select Your Licensed Molecules

Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!

Get a Quote

Receive a confidential, non-binding quote for the molecule(s) you choose.

Get Qualified & We Deliver

Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.

Explore our Shop

Do you have a question you'd like to ask us?

Here’s how to get started:

Reach out to our team - we'd be happy to help you!

+49 (0) 30 959 99 8832
info@evidentic.com

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.